Advertisement
TLRY vs YCBD
Which Stock Would AI Choose? Tilray Brands (TLRY) vs. cbdMD (YCBD) Stock Comparison
Key Takeaways
- Tickeron AI Verdict: TLRY is the favored ticker of the two, based on its larger scale, diversified revenue base, stronger liquidity, and more consistent market positioning relative to YCBD.
- TLRY operates a multi-segment cannabis, beverage, and wellness platform with fiscal-year revenue near $915 million, while YCBD is a micro-cap CBD brand with roughly $5.6 million in quarterly net sales.
- Both companies remain unprofitable, but TLRY holds a substantially larger cash position and more diversified revenue streams, while YCBD carries a much thinner balance sheet.
- YCBD is growing revenue at a faster percentage rate and benefits from a new federal Medicare CBD pathway, but its small scale and regulatory exposure present higher risk.
- Explore further context on each name via TLRY Major News and TLRY Today's Price Move, as well as YCBD Major News and YCBD Today's Price Move.
- To see how AI-driven strategies are navigating names like these, visit the Trending AI Robots page.
Introduction
Investors tracking the cannabis and hemp-derived wellness sector often weigh established, diversified operators against smaller, higher-growth pure plays. This stock comparison examines TLRY (Tilray Brands, Inc.) and YCBD (cbdMD, Inc.), two publicly traded companies with exposure to overlapping regulatory and consumer themes but sharply different business models. Understanding their relative performance and market positioning can help traders assess whether scale and diversification or growth potential and specialization better suit their objectives in the current environment.
TLRY Overview and Recent Performance
TLRY, Tilray Brands, Inc., has evolved from a cannabis producer into a diversified consumer packaged goods company spanning cannabis, craft beverages, and wellness products. The company posted record fiscal-year revenue near $915 million, supported by growth across its distribution, beverage, and international medical cannabis segments. In recent weeks, management has emphasized international expansion, including strengthening Canadian cultivation and expanding European medical distribution, alongside the integration of craft-beer acquisitions such as BrewDog.
Despite operational progress, the stock has traded under sustained pressure, falling roughly 50% through much of 2026 and hovering near its 52-week lows. Sentiment has been shaped by persistent unprofitability, competition in the crowded cannabis market, and broader investor caution toward speculative, cash-burning names. Analysts remain divided, with some maintaining buy ratings while others express caution, reflecting a stock whose fundamentals are improving but whose profitability remains unproven.
YCBD Overview and Recent Performance
YCBD, cbdMD, Inc., is a smaller operator focused on CBD and hemp-derived wellness products under brands including cbdMD, Paw CBD, Bluebird Botanicals, and the Oasis THC beverage line. The company has delivered double-digit year-over-year revenue growth, with recent quarterly net sales of approximately $5.6 million and sequential gains, aided by the integration of the Bluebird Botanicals acquisition completed in early 2026.
Recent market activity has been influenced by regulatory developments, including the activation of a federal Medicare pathway for hemp-derived CBD products, which management views as a long-term growth opportunity. However, the company continues to report operating losses and maintains a limited cash balance, while shifting state-level rules have raised compliance and repackaging costs. This combination of strong percentage growth, evolving catalysts, and a constrained balance sheet defines YCBD's risk-reward profile.
Trending AI Robots
For traders seeking a more systematic approach, Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a broader universe of hundreds of available bots that collectively monitor thousands of tickers. Only the strategies best suited to current market conditions are featured in this section. Each bot operates with its own trading style, timeframe, performance history, and watchlist of tickers, giving investors a range of quantitative approaches to consider alongside traditional fundamental analysis. Explore the Trending AI Robots page to review the current lineup and assess which strategies align with your market view.
Head-to-Head Comparison
The most striking contrast between these two names is scale. TLRY generates hundreds of millions of dollars in quarterly revenue across multiple segments and geographies, whereas YCBD operates at a fraction of that size within a narrower CBD-focused niche. This difference translates into divergent risk profiles: TLRY benefits from diversification and a more substantial cash cushion, while YCBD offers faster relative growth but with thinner liquidity and greater sensitivity to any single regulatory or integration setback.
Growth drivers also differ. TLRY is leaning on international medical cannabis expansion and craft-beverage integration, whereas YCBD is positioned around hemp-derived wellness products and an emerging Medicare pathway. Both face regulatory and competitive headwinds, but YCBD's micro-cap structure and concentrated exposure make its downside risk comparatively higher.
Tickeron AI Verdict
Based on observable factors such as trend consistency, financial stability, catalyst breadth, and relative market positioning, Tickeron's AI framework would likely favor TLRY over YCBD in the current environment. While both companies are unprofitable and face regulatory uncertainty, TLRY's diversified revenue streams, larger cash reserves, and expanding international footprint provide a more stable foundation. YCBD's faster revenue growth and federal pathway catalyst are notable, but its limited scale and balance sheet introduce greater variability. As a result, TLRY currently appears better positioned on a relative, risk-adjusted basis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TLRY is a Buy and YCBD is a Hold.
TLRY's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for TLRY turned positive on November 04, 2026. Looking at past instances where TLRY's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TLRY's RSI Indicator exited the oversold zone, 40 of 50 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +16.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 46 cases where TLRY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLRY as a result. In 71 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TLRY entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (6.379). P/E Ratio (-2.679) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
YCBD's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for YCBD turned positive on October 21, 2026. Looking at past instances where YCBD's MACD turned positive, the stock continued to rise in 33 of 38 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where YCBD's RSI Oscillator exited the oversold zone, 32 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on YCBD as a result. In 85 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +9.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where YCBD advanced for three days, in 148 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 33 cases where YCBD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where YCBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
YCBD broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for YCBD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.568) is normal, around the industry mean (6.379). P/E Ratio (1.809) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. YCBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YCBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
TLRY | YCBD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 22 Undervalued | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 93 | 98 | |
PRICE GROWTH RATING 1..100 | 86 | 79 | |
P/E GROWTH RATING 1..100 | 14 | 27 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TLRY's Valuation (22) in the Biotechnology industry is in the same range as YCBD (42) in the Other Consumer Services industry. This means that TLRY’s stock grew similarly to YCBD’s over the last 12 months.
TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as YCBD (100) in the Other Consumer Services industry. This means that TLRY’s stock grew similarly to YCBD’s over the last 12 months.
TLRY's SMR Rating (93) in the Biotechnology industry is in the same range as YCBD (98) in the Other Consumer Services industry. This means that TLRY’s stock grew similarly to YCBD’s over the last 12 months.
YCBD's Price Growth Rating (79) in the Other Consumer Services industry is in the same range as TLRY (86) in the Biotechnology industry. This means that YCBD’s stock grew similarly to TLRY’s over the last 12 months.
TLRY's P/E Growth Rating (14) in the Biotechnology industry is in the same range as YCBD (27) in the Other Consumer Services industry. This means that TLRY’s stock grew similarly to YCBD’s over the last 12 months.
| TLRY | YCBD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Advances ODDS (%) | 8 days ago 79% | 9 days ago 80% |
| Declines ODDS (%) | 2 days ago 90% | 7 days ago 90% |
| BollingerBands ODDS (%) | N/A | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
TLRY’s FA Score shows that 2 FA rating(s) are green while YCBD’s FA Score has 1 green FA rating(s).
- TLRY’s FA Score: 2 green, 3 red.
- YCBD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
TLRY’s TA Score shows that 3 TA indicator(s) are bullish while YCBD’s TA Score has 4 bullish TA indicator(s).
- TLRY’s TA Score: 3 bullish, 4 bearish.
- YCBD’s TA Score: 4 bullish, 4 bearish.
Price Growth
TLRY (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while YCBD (@Pharmaceuticals: Generic) price change was -8.42% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
Reported Earning Dates
YCBD is expected to report earnings on Dec 18, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.20% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
YCBD and
Correlation & Price change
A.I.dvisor indicates that over the last year, YCBD has been loosely correlated with TRLV. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if YCBD jumps, then TRLV could also see price increases.
| Ticker / NAME | Correlation To YCBD | 1D Price Change % | ||
|---|---|---|---|---|
| YCBD | 100% | +0.71% | ||
| TRLV - YCBD | 48% Loosely correlated | +0.73% | ||
| GLAS - YCBD | 43% Loosely correlated | +2.60% | ||
| TLRY - YCBD | 41% Loosely correlated | -7.02% | ||
| CRON - YCBD | 25% Poorly correlated | -3.67% | ||
| DERM - YCBD | 24% Poorly correlated | -2.21% | ||
More | ||||